Cannaisseur Group Inc. SEC filings TCRG
Cannaisseur Group Inc. has 72 filings in SEC EDGAR's recent list, going back to Feb 14, 2022. Its latest annual report, Form 10-K, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 28, 2025 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 28, 2025 | Aug 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
May 5, 2025 | Apr 30, 2025 |
| 8-K |
Current report
Other events
|
Mar 21, 2025 | Mar 21, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 6, 2025 | Dec 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 6, 2025 | Mar 12, 2024 |
| 8-K |
Current report
Other events
|
Feb 5, 2025 | Jan 31, 2025 |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TCRG (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1879270
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.